Johnson & Johnson announced that Health Canada has issued a Notice of Compliance for Lazcluze in combination with Rybrevant for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations. Janssen, a Johnson & Johnson company, is the market authorization holder for Lazcluze/Rybrevant in Canada.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson reports ‘positive’ results from Phase 2b study of icotrokinra
- Johnson & Johnson announces new icotrokinra data from Phase 3 program
- CDC plans study into potential vaccines, autism connections, Reuters reports
- Johnson & Johnson discontinues depression program for aticaprant
- Neumora Therapeutics downgraded to Neutral from Buy at Guggenheim